Exercise mimetics

An exercise pill (or full exercise mimetic) is a pharmacological or nutraceutical agent (such as but not limited to a synthetic drug, a receptor agonist, or a plant‑derived phytochemical) that is designed to reproduce, at least partially, the complex, multisystemic benefits normally conferred by regular physical activity in human. In other words, it seeks to trigger key molecular pathways (e.g., AMPK, PPAR β/δ, REV‑ERBα, ERRs, SIRT‑1, adiponectin signaling) and downstream effects such as enhanced mitochondrial biogenesis, improved insulin sensitivity, anti‑inflammatory signaling, vascular endothelial function, autonomic balance, and the release of "exerkines" (e.g., NO·, VEGF, IL‑6, myokines) that together drive cardiometabolic health. While a true "full" exercise mimetic would need to replicate the integrated, time‑varying stimulus that each exercise bout provides across multiple organs (muscle, heart, vasculature, liver, adipose tissue, brain, and gut microbiota), most current candidates achieve only a subset of these adaptations, acting as exercise‑mimetic agents that can augment or partially substitute for the physiological cascade generated by exercise.

There are many different kinds of exercise in humans. An exercise mimetic would specifically target one type of exercise, it does not seem plausible to get all the benefits of all the different kinds of exercise in a single exercise mimetic intervention (for example: adaptation through exercise to a marathon runner physique but also a bodybuilder weightlifting adaptation, or other physiques that would be mutually exclusive).

Exercise mimetics

References

Mimicking exercise: what matters most and where to next? (2018 or 2020)

Exercise pills for cardiometabolic health cannot mimic the exercise milieu (2025)

"Many exercise-induced adaptations are inherently linked to acute biological stimuli triggered by exertion (e.g., increased arterial shear stress, adrenaline secretion, transient tissue damage in the form of oxidative stress, or acute inflammation). Such stimuli are virtually impossible to reproduce by taking a pill." therefore any exercise mimetic would likely require non-pill physical interventions. For example, temporary pressure changes exterior to the body or via mechanical compression, etc... it's important also to note that isometric exercise seems to produce muscular hypertrophy, e.g. it's not the full lift that matters; maybe still work to be done on understanding molecular basis of exercise results.

Various interventions

electrical stimulation, neuromuscular electrical stimulation, functional electrical stimulation
passive limb cycling, whole-body vibration
blood flow restriction
ultrasound stimulation, massage, deep tissue massage
acupuncture
passive heat therapies - hot water immersion, sauna, steam, cold water plunges, cold showers
cold blood infusion
atmospheric pressure therapy, oxygen supplementation
blood doping
gut microbiome related interventions
anabolic steroid therapy

Trainable human physiques

The following has some information about genetics to achieve certain physiques, but really what would be more interesting is more rapid genetic capacity for switching between these phenotypes through simple training. Some of this information is from the germline genetic modification proposals page.

Max strength

Max strength or mass: Dominated by extreme myofibrillar hypertrophy (very large Type II muscle fibers), high neural drive for maximal motor-unit recruitment, thick connective tissue, and elevated bone mineral density. Muscles are optimized to produce huge force over short durations, relying on phosphocreatine and glycolytic energy rather than oxygen metabolism. Body mass is high because leverage and inertia aid maximal strength output.

Muscle size: myostatin (GDF8) knockout, follistatin, or muscle‑specific ActRII decoy (e.g., ACVR2B knockout); muscle hyperplasia via myofiber-specific TEAD1 overexpression (drives satellite-cell hyperplasia for more Pax7+ progenitors), missense mutant myostatin (C313Y for hyperplasia without hypertrophy), or beta-catenin (Ctnnb1) activation in progenitors.
Anabolic signaling: muscle-restricted IGF‑1 (mIGF-1, α-actin, or MCK promoters) to drive the Akt‑mTORC1 axis; conditional muscle AKT1 activation (myr-AKT1) for fiber hypertrophy and higher grip/peak force.
Protein synthesis: boost myofibrillar protein synthesis; ensure that the enlarged fibers are packed with contractile proteins rather than merely excess sarcoplasm; muscle-restricted S6K1 modulation or rapamycin-informed hypomorphs for balanced mTOR anabolic signaling.
Fiber identity: expression of PGC‑1α4, a splice variant that up‑regulates IGF‑1 while repressing myostatin; ACTN3 gain-of-function (Arg577 or rs1815739 R allele mimic) to maintain fast-twitch identity and power.
Fiber composition: try to bias fiber composition toward large, fast‑glycolytic Type IIx/IIb cells via FOXO1/3/4 triple knockout (suppresses atrophy, preserves strength into aging).
Bone density: raise cortical thickness and bone mineral density via Sost (sclerostin) knockout or systemic sclerostin‑neutralising antibody (romosozumab); LRP5 gain-of-function for extra strong bones; GPR133/ADGRD1 enhancement for mechanosensitive bone formation; intermittent PTH analogues (teriparatide).
Neural drive: muscle hyperinnervation: muscle GDNF overexpression, LRP4 overexpression (improves NMJ structure/innervation, grip strength), DOK7 overexpression (enlarges NMJs, improves torque/motor function), or high MuSK overexpression (HSA::MuSK transgene for ectopic synapses and extra innervation).
Anabolic pharmacology: anabolic steroid analogues (testosterone or SARMs such as ostarine) and low‑dose β2‑adrenergic agonists (clenbuterol) synergise with the IGF‑1/mTOR axis, further increasing protein synthesis and satellite‑cell recruitment.
Energy substrate: creatine monohydrate supplementation to expand intramuscular phosphocreatine stores; muscle creatine kinase (CKM) transgene; high protein diet.
Sports genotype boosts: ACE D allele (rs4646994), ACTN3 Arg577, AMPD1 Gln12, HIF1A 582Ser, MTHFR rs1801131 C, NOS3 rs2070744 T, PPARG 12Ala.

Muscular hypertrophy

Muscular hypertrophy: Characterized by both myofibrillar growth and sarcoplasmic hypertrophy, meaning fibers grow large but also swell with glycogen, fluid, and enzymatic volume, creating the “round” look. High training volume increases local blood flow and metabolite tolerance. Mitochondrial and cardiovascular adaptations are moderate. Strength rises but is secondary to muscle symmetry and maximal cross-sectional area.

Myostatin pathway: myostatin knockouts (GDF8), follistatin overexpression, or bimagrumab (activin type II receptor targeting); muscle-specific follistatin (FST) transgenes; ACVR2B muscle-specific knockout.
Hyperplasia: muscular hyperplasia targets: TEAD1 myofiber-specific overexpression (satellite-cell hyperplasia), Fn14 (Tnfrsf12a) in satellite cells (increases proliferation/self-renewal), Tcf4+ fibroblasts / PDGFRα+ FAPs regulation, or myostatin C313Y missense mutant.
Anabolic signaling: muscle-restricted IGF1 (α-actin/MCK promoters) for postnatal mass/strength; conditional AKT1 activation for fast glycolytic fiber growth.
Metabolic support: PEPCK-C muscle overexpression for improved metabolism/endurance synergy with hypertrophy.
Anabolic pharmacology: anabolic steroids enhance mass with/without exercise; combine with exercise for maximal gains.

Explosive power or speed

Explosive power or speed: Built around large and highly reactive Type II fast-twitch fibers, maximal motor-unit firing speed, elastic muscle-tendon stiffness, and a nervous system adapted for rapid contraction. Emphasis is on producing maximal force quickly rather than generating peak force overall. Uses phosphocreatine energy systems, creating dense but relatively compact musculature.

Fast fiber shift: promote fast myosin heavy chain isoforms (MYH1/MYH4 overexpression or MYH7 slow-fiber suppression) to shift toward Type IIx/IIb fibers with higher unloaded shortening velocity; ACTN3 gain-of-function (rs1815739 R/Arg577 for sprinting/power).
Calcium handling: enhance sarcoplasmic reticulum Ca²⁺ handling via SERCA1 upregulation and parvalbumin overexpression for faster twitch kinetics and relaxation.
Energy systems: boost phosphocreatine system with muscle creatine kinase (CKM) transgene or chronic creatine supplementation to maximize rapid ATP resynthesis during short, high-power bursts.
Tendon stiffness: increase tendon stiffness and elasticity through scleraxis (SCX) or Mohawk (Mkx) overexpression in tenocytes, or Col1a1 enhancers for optimized collagen fibril alignment and energy storage.
Neural transmission: heighten neural conduction and firing rates via voltage-gated sodium channel (Nav1.6/Scn8a) gain-of-function or acetylcholinesterase (AChE) inhibition to prolong neuromuscular junction signaling.
β2-adrenergic receptor (β2-AR) activation (e.g., clenbuterol or transgenic overexpression) to selectively hypertrophy fast-twitch fibers while improving excitation-contraction coupling.
Fast-twitch maintenance: suppress slow-fiber conversion by inhibiting calcineurin-NFAT signaling or AMPK/PGC-1α1 pathways, preserving the fast/glycolytic phenotype; ACE D allele (rs4646994) for fast-twitch bias.
Thyroid hormone: thyroid hormone receptor (TRα1) modulation or short-term T3 supplementation to accelerate myosin isoform switching toward faster variants.
Satellite cells: transgenic overexpression of Pax7 specifically in muscle satellite cells (HsMusTR promoter) to expand quiescent progenitors for Type II repair; Wnt7a for symmetric Pax7+ division; Myf5/MyoD under MYH1 promoters for Type II skew; Notch (NICD/Hes1) for proliferative progenitors.
Myostatin inhibition: muscle myostatin inhibition via MYH1-driven follistatin for Type II-biased hyperplasia.
Muscle hyperinnervation: LRP4/DOK7/MuSK for NMJ enlargement and extra synapses; PGC-1α for "training-like" NMJ remodeling.
Sports boosts: HGH/IGF1 for power/recovery; PPAR-delta for slow-twitch but adaptable to power via fat metabolism.

Durability

Durability: Built to maximize tissue resilience and sustained work output under mechanical stress, this physique emphasizes moderate fiber hypertrophy (Type I and IIa), dense connective tissues, elevated bone mineral density, and neuromuscular systems adapted to maintain coordination under fatigue. Aerobic capacity is strong but secondary to the ability to support prolonged load carriage, awkward movements, impact exposure, heat stress, and sleep or calorie restriction. Compared to endurance athletes, durability bodies are metabolically less efficient but mechanically tougher—capable of working for long periods with heavy equipment and structural strain without breakdown, even though they lack elite long-distance speed or maximal oxygen-use efficiency.

Fiber composition: bias fiber composition toward fatigue-resistant Type I and oxidative Type IIa fibers via muscle-specific PGC-1α1 overexpression or ERRα activation to boost mitochondrial biogenesis, capillary density, and myoglobin content for sustained ATP production under prolonged stress; longevity-aligned mito enhancements like mitochondria-targeted catalase (mCAT), OPA1 (cristae integrity), or Parkin/ATG5 (mitophagy).
Connective tissue: enhance connective tissue resilience with scleraxis (SCX) and Mohawk (Mkx) overexpression in tenocytes/ligament fibroblasts, coupled with lysyl oxidase (LOX) upregulation for superior collagen cross-linking and tensile strength against repetitive strain; biglycan (Bgn)/decorin (Dcn) for ECM organization/hydration.
Tendon adaptability: increase tendon and ligament adaptability via biglycan (Bgn) and decorin (Dcn) transgenes to improve ECM organization, hydration, and shock absorption during impact or awkward loading.
Bone density: elevate bone mineral density and cortical thickness with sclerostin (Sost) knockout, LRP5 gain-of-function, or romosozumab/romosozumab administration, plus intermittent PTH (teriparatide) for dynamic remodeling under heavy load carriage; GPR133/ADGRD1.
Excitation-contraction coupling: improve excitation-contraction coupling for fatigue resistance through SERCA2a and calsequestrin 1 (Casq1) upregulation, enabling sustained Ca²⁺ handling and twitch force maintenance during extended efforts.
Stress tolerance: boost proteostasis and stress tolerance with HSP70/HSPA1A and HSP90AA1 overexpression, conferring resilience to mechanical damage, heat stress, hypoxia, and proteotoxic insults from calorie/sleep restriction; TFEB overexpression for lysosomal biogenesis/autophagy (LysoSENS-inspired); Klotho heterozygosity/overexpression for systemic stress resistance.
Metabolic flexibility: promote metabolic flexibility and anti-catabolic defenses via PPARδ or SIRT1 muscle-specific transgenes, enhancing fat oxidation, autophagy regulation, and IGF-1 resistance to preserve muscle under nutrient scarcity or prolonged activity; PEPCK-C for endurance metabolism.
Satellite cell repair: augment satellite cell-mediated repair under fatigue via Pax7+ progenitor expansion (Wnt7a or Notch signaling activation) biased toward Type I/IIa differentiation, ensuring rapid tissue homeostasis without excessive hypertrophy; FOXO triple knockout for strength preservation.
Longevity genes: durability via longevity genes: SIRT6/FOXO3 for stress resilience; senescent cell clearance (INK-ATTAC); hyaluronan from naked mole rats (HAS2 high-activity) for ECM hydration/inflammation control.

Endurance

Endurance: Built to maximize movement efficiency and sustained oxygen delivery, this physique is defined by extreme mitochondrial density, expansive capillary networks, and dominance of Type I slow-twitch fibers optimized for fatigue resistance at low force output. Cardiovascular adaptations (large stroke volume, high VO₂max) dominate, while muscle size and connective tissue remain minimal to reduce body mass and energy cost. This makes endurance athletes exceptionally efficient for long, unloaded, repetitive movement—but structurally fragile under heavy external loads or impact, with lower bone density, tendon thickness, and joint robustness compared to more load-tolerant physiques.

Fiber switch: bias fiber composition toward fatigue-resistant Type I slow-twitch fibers via muscle-specific PGC-1α1/β overexpression, calcineurin-NFAT activation (e.g., CnAβ transgene), MEF2C upregulation, or slow myosin heavy chain isoforms (MYH7 overexpression with MYH1/MYH4 suppression); ACTN3 loss-of-function (rs1815739 XX) for endurance bias.
Mitochondrial density: boost mitochondrial biogenesis and oxidative capacity with ERRα/ERRγ nuclear receptor activation (e.g., transgenic overexpression, MCK::ERRα, or agonists like SLU-PP-332), elevating electron transport chain components, fatty acid oxidation enzymes, and ATP production efficiency; mito catalase (mCAT), PRDX3/GPx4 for ROS control, Mclk1+/- for ROS signaling.
Metabolic flexibility: enhance fat oxidation and metabolic flexibility via PPARδ (PPARD) muscle-specific overexpression or agonists (e.g., GW501516), synergizing with AMPK activation (e.g., AICAR, Prkaa1/2 gain-of-function, or AMPKα1) to upregulate CPT1, UCP3, HADH, glucose uptake (GLUT4), and suppress mTOR-driven hypertrophy; PPARGC1A rs148144750 variant.
Capillarization: promote extensive capillary angiogenesis and oxygen diffusion with muscle-targeted VEGF-A, angiopoietin-1 (Ang1/ANGPT1), or local HIF-1α stabilization, increasing capillary-to-fiber ratio alongside myoglobin (MB) transgene overexpression for superior intracellular O₂ storage and delivery; systemic EPO/HIF for RBC/hemoglobin boost.
Oxygen transport: elevate systemic oxygen carrying capacity through liver/kidney-specific EPO overexpression or HIF-1α stabilization (e.g., PHD2 knockout), boosting erythropoiesis and hemoglobin mass to enhance VO₂max.
Lactate handling: amplify endurance metabolism with muscle PEPCK-C (PEPCK-M) overexpression for gluconeogenesis from lactate/fatty acids, combined with MCT1/MCT4 for lactate shuttling and pH buffering.
Excitation-contraction coupling: improve neuromuscular and excitation-contraction coupling for low-force endurance via SERCA2a upregulation (skeletal and cardiac), calsequestrin 2 (Casq2), parvalbumin suppression for sustained low-frequency firing, and SIRT1 transgenes for PGC-1α deacetylation and proteostasis; muscle hyperinnervation (DOK7/LRP4) for sustained function.
Endurance genotype: shift toward endurance genotype via ACE I-allele (rs4646994), PPARA rs4253778 G, PPARGC1A Gly482.
Cardiac support: cardiac-specific interventions like SERCA2a overexpression or β1-adrenergic receptor modulation to enlarge stroke volume and cardiac output, complementing skeletal muscle aerobic capacity; FGF21 transgenic for metabolic shift.
Longevity for mitochondria: mtDNA copy number increase, allotopic expression (MitoSENS), lower PUFA peroxidation index.

Strength-to-weight

Strength-to-weight or skill: Optimized for maximal relative strength rather than absolute strength, featuring highly efficient neural activation, dense connective tissues, stiff tendons, and compact musculature with minimal sarcoplasmic bloat. Body fat remains extremely low. Muscles are smaller but capable of producing enormous force per unit of mass due to neuromuscular precision and tendon recoil.

Fiber bias: bias fiber composition toward compact, high-specific-force Type IIx fibers via ACTN3 R577 gain-of-function (alpha-actinin-3 overexpression), MYH1/MYH4 fast myosin heavy chain promotion, and suppression of slow MYH7 isoforms to maximize force-velocity without sarcoplasmic expansion; ACE D/I balance.
Neural efficiency: enhance neural drive and motor-unit efficiency with Nav1.6 (Scn8a) gain-of-function mutations or overexpression for faster action potential propagation, coupled with agrin (Agrin) transgene or mini-agrin secretion to strengthen neuromuscular junctions and voluntary activation; MuSK for extra NMJs.
Tendon recoil: increase tendon stiffness and recoil energy storage through scleraxis (SCX) and Mohawk (Mkx) overexpression in tenocytes, plus lysyl oxidase (LOX) upregulation for dense collagen cross-linking, optimizing elastic return without added mass.
Myofibrillar packing: promote myofibrillar density over sarcoplasmic hypertrophy by muscle-specific Akt-mTORC1 activation (e.g., muscle-restricted IGF-1Ea) combined with glycogen synthase kinase-3β (GSK3β) inhibition to pack contractile elements tightly while limiting glycogen/fluid bloat; S6K1 hypomorph for leanness.
Leanness: minimize body fat and enhance leanness via muscle-targeted PPARδ or AMPKα1 overexpression to boost fat oxidation and suppress adipogenesis, synergizing with PRDM16 in adipose precursors for thermogenic browning and low mass.
Titin stiffness: elevate passive muscle stiffness and specific tension with giant elastic protein titin (TTN) N2A region stiffening mutations or overexpression, improving force transmission per fiber cross-section without hypertrophy.
Skill precision: boost cortical motor neuron excitability and skill precision through BDNF/TrkB signaling enhancement (e.g., muscle-derived BDNF transgene) to enlarge motor cortex representation and refine proprioceptive feedback for relative strength feats.
Hyperplasia without size: suppress myostatin (MSTN) selectively in fast-twitch progenitors via MYH1 promoter-driven follistatin to enable fiber hyperplasia (more motors) without overall size increase, amplifying force per unit mass; TEAD1 hyperplasia without baseline size increase.
Proteostasis: muscle proteostasis: TFEB/HSPs for durability under low mass.

Mixed power-endurance

Mixed power-endurance: Combines moderate muscle hypertrophy with strong aerobic capacity, producing muscles that hold both sizable fibers and high mitochondrial density. Energy systems are highly flexible—both anaerobic power and aerobic endurance are well developed. Lactate clearance and oxidative recovery adaptations are prominent, enabling repeated high-output efforts without extreme specialization.

Fiber hybridization: balance fiber composition toward glycolytic-oxidative Type IIa intermediates via muscle-specific calcineurin-NFAT (CnAβ/NFATc1) overexpression moderated by AMPKα1 to prevent full Type I conversion, preserving power while enhancing fatigue resistance for repeated efforts; ACTN3 heterozygote mimic.
Mitochondrial + hypertrophy: synergize PGC-1α1 (for mitochondrial biogenesis) with PGC-1α4/IGF-1Ea transgenes to drive moderate myofibrillar hypertrophy alongside high OXPHOS density, enabling sizable fibers with robust aerobic recovery; ERRα/PPARδ combo.
Lactate shuttle: upregulate lactate shuttling and oxidation via MCT1/MCT4 and LDHB (lactate dehydrogenase B) muscle overexpression, coupled with PEPCK-C for lactate-fueled gluconeogenesis, optimizing pH buffering and energy recycling between anaerobic bursts.
Metabolic flexibility: activate PPARδ (via agonists like GW501516 or PPARD transgene) alongside low-dose β2-adrenergic stimulation (clenbuterol) to boost fat oxidation and fast-fiber power without suppressing mTOR-driven protein synthesis; glucagon-like peptide 1 for glucose/lactate management.
Excitation-contraction coupling: promote hybrid excitation-contraction coupling with SERCA1/2a co-upregulation and calsequestrin 1/2 (Casq1/2) expression for rapid Ca²⁺ reuptake during high-repetition power output and sustained low-force phases.
Myostatin moderation: moderate myostatin inhibition using muscle-targeted follistatin (FST) or bimagrumab at sub-maximal doses, favoring Type IIa hyperplasia and satellite cell (Pax7+) recruitment biased toward mixed progenitors via Wnt7a/Notch modulation; Fn14 for self-renewal.
Metabolic recovery: enhance metabolic flexibility and recovery with SIRT1/PPARγ co-activation (muscle-specific transgenes) to regulate PGC-1α deacetylation, autophagy, and anti-catabolic IGF-1 signaling under fluctuating energy demands; FGF21/adiponectin overexpression.
Capillary support: boost capillary-to-fiber ratio and O₂ delivery via VEGF-A/Ang1 transgenes moderated by HIF-1α stabilization, supporting oxidative recovery without excessive vascularization that could dilute fiber density; EPO for hybrid VO2.
Proteostasis: improve proteostasis for repeated stress via HSP70/HSP90AA1 overexpression, conferring resilience to metabolic byproducts, mechanical fatigue, and intermittent nutrient loads in hybrid training regimens; Klotho/FGF21 for endocrine resilience.